TRIM11 (tripartite motif-containing protein 11), an E3 ubiquitin ligase, is known to be involved in the development of the central nervous system. However, very little is known regarding the role of TRIM11 in cancer biology. Here, we examined the expression profile of TRIM11, along with two stem cell markers CD133 and nestin, in multiple glioma patient specimens, glioma primary cultures derived from tumors taken at surgery and normal neural stem/progenitor cells (NSCs). The oncogenic function of TRIM11 in glioma biology was investigated by knockdown and/or overexpression in vitro and in vivo experiments. Our results showed that TRIM11 expression levels were upregulated in malignant glioma specimens and in high-grade glioma-derived primary cultures, whereas remaining low in glioblastoma multiforme (GBM) stable cell lines, low-grade glioma-derived primary cultures and NSCs. The expression pattern of TRIM11 strongly correlated with that of CD133 and nestin and differentiation status of malignant glioma cells. Knock down of TRIM11 inhibited proliferation, migration and invasion of GBM cells, significantly decreased epidermal growth factor receptor (EGFR) levels and mitogen-activated protein kinase activity, and downregulated HB-EGF (heparin-binding EGF-like growth factor) mRNA levels. Meanwhile, TRIM11 overexpression promoted a stem-like phenotype in vitro (tumorsphere formation) and enhanced glial tumor growth in immunocompromised mice. These findings suggest that TRIM11 might be an indicator of glioma malignancy and has an oncogenic function mediated through the EGFR signaling pathway. TRIM11 overexpression potentially leads to a more aggressive glioma phenotype, along with increased malignant tumor growth and poor survival. Taken together, clarification of the biological function of TRIM11 and pathways it affects may provide novel therapeutic strategies for treating malignant glioma patients.
INTRODUCTION
Malignant gliomas are the most common primary tumors in the central nervous system and are characterized by rapid cell proliferation, high invasiveness, genetic alteration and increased angiogenesis. 1 Despite continued advances in surgical and medical therapeutics, the prognosis for patients diagnosed with the most common and aggressive malignant gliomaglioblastoma multiforme (GBM)-remains poor, with a median survival of only 12-15 months. 2 In recent years, glioma molecular markers such as MGMT (O 6 -methylguanine-DNA methyltransferase), EGFR (epidermal growth factor receptor) and IDH1 (isocitrate dehydrogenase-1) have had important roles in profiling the diagnosis, prognosis and disease management in subtypes of glioma patients. 2, 3 More recently, CD133 (prominin-1) and nestin have been considered as prognosis markers for glioma patients as their expression is associated with poor prognosis and correlates better with clinical course than the histological grading. 4, 5 They are also used as markers for glioma stem-like cells (GSCs), a small subset of tumor cells situated at the apex of the cellular differentiation hierarchy and responsible for sustaining long-term tumor growth through self-renewal and the production of more differentiated daughter cells. [6] [7] [8] GSCs are known to contribute to tumorigenesis and radiation resistance in malignant glioma 9 and are regulated via many signaling pathways, including Notch, Hedgehog and MAPK (mitogen-activated protein kinase) cascades and so on. 10 Due to the malignancy-driving roles of GSCs, drugs that specifically target the GSCs have a very important potential role in glioma therapy. 11 However, both CD133 and nestin are also present on nonmalignant neural stem/progenitor cells (NSCs), 12, 13 and targeting GSCs through these markers will likely damage NSCs. This is particularly problematic in the brain, as damage to NSCs resulting from glioma therapies 14 can produce profound cognitive side effects that impair patient's functional independence and quality of life. 15, 16 The tripartite motif-containing (TRIM) family is characterized by unique structural motifs: a RING finger domain, a B-box domain and a coiled-coil domain, making them members of the RING B-box coiled-coil (RBCC) protein family. [17] [18] [19] Members of this family have been implicated in various cellular processes, including development, neurodegenerative diseases, cellular response to viral infection and cancer. 20 As a typical RBCC protein, TRIM11 functions as an E3 ubiquitin ligase and binds to and destabilizes Humanin, a neuroprotective peptide against Alzheimer's disease-relevant insults. 21 In addition, TRIM11 interacts with and destabilizes the activator-mediated cofactor complex (ARC105), which in turn suppresses ARC105-mediated transcriptional activation induced by transforming growth factor b signaling. 22 TRIM11 also binds to and mediates the ubiquitination of PAX6 (paired box 6), a member of the PAX family of transcription factors and has a key role in organogenesis of the eye, pancreas and brain. 23 Finally, TRIM11 is involved in the specification of noradrenergic phenotype by interacting with Phox2b, a homeodomain transcription factor that could modulate development of noradrenergic neurons. 24 These findings implicate an important, albeit still incompletely defined, role of TRIM11 in the function and development of nervous system. Nonetheless, an oncogenic function of TRIM11 has yet to be identified in cancer cells of glial origin that shares a lot of common characteristics with the normal glial cells of the brain. 25 In this study, we not only provide evidence that TRIM11 expression levels correlate with the malignancy of glioma but also investigate the oncogenic function of TRIM11 in vitro and in vivo.
RESULTS
TRIM11 is over-expressed in human high-grade glioma tumors and glioma-derived GSCs but not in NSCs, low-grade glioma-derived GSCs or stable malignant glioma cell lines To investigate the correlation between TRIM11 and malignancy of glioma, immunohistochemical analysis of TRIM11 was performed using patient-derived glioma samples ( Figure 1a ). Strong TRIM11 staining was detected in GBM tissues but much less in the Grade II and normal brain tissues (representative results shown). Next, we profiled TRIM11 mRNA levels using 19 diverse histological primary GSCs derived from glioma patients (Table 1), four stable GBM cell  lines (U-251, D-54, LN229 and U-87) and three NSCs (SC23, SC27  and SC30) . Overall, TRIM11 was low in all the GBM cell lines, 6 of 7 (85.7%) low-grade GSCs and all NSCs (normalized fold expression o2.5). By comparison, 1 of 3 (33.3%) Grade III-GSCs and 7 of 9 (78%) GBM-GSCs had higher levels of TRIM11 (normalized fold expression 42.5; Table 1 and Supplementary Figure S1a) . The expression pattern of TRIM11 in cells was further confirmed at the protein levels. Western blotting data showed that TRIM11 expressed higher in GBM-GSCs (Supplementary Figure S1b) , consistent with its mRNA levels. To evaluate the role of TRIM11 on clinical prognosis, we compared the outcome of patients with different expression levels of TRIM11. As shown in Table 1 (survival data), the high-grade glioma patients with lower TRIM11 had a better prognosis (average 13.5-month survival for GBM patients) compared with patients with higher TRIM11 (average 7.3-month survival for GBM patients).
Next, we compared TRIM11 mRNA levels to those of CD133. Consistent with a previous report, 26 the three NSC cultures displayed excessively high CD133 (up to 3000-fold normalized expression). Although all stable GBM cell lines and low-grade glioma-derived GSCs (except DB51) showed very low CD133, CD133 was strongly expressed in all GBM-GSCs, and in one Grade III GSC TRIM11 has oncogenic functions in gliomas K Di et al (Table 1 and Supplementary Figure S1a) . Our results were consistent with previous reports 4,5 that high CD133 mRNA levels correlate with glioma malignancy. More importantly, GSCs with elevated TRIM11 expressed concurrently higher CD133 (shading in Table 1 ). For example, the two GBM-GSCs (DB32 and HuTuP01) that showed the highest levels of TRIM11 (29.25 and 13.78-fold, respectively) also displayed the highest levels of CD133 (66.07 and 27.34-fold, respectively), indicating a positive correlation between TRIM11 and CD133 in gliomas. Next, we performed immunofluorescent double staining to further compare the expression parallel between CD133 and TRIM11 using corresponding tissue sections. As shown in Figure 1b , both DB44 (Grade II) and DB32 (GBM) revealed co-expression of TRIM11 and CD133, but the strong immunopositivity was detected only in DB32. HuTuP01-GSC was used to confirm these data. As shown in Figure 1c , TRIM11 was not only localized diffusely mainly in the cytoplasm but also in the nucleoplasm (top), which was consistent with previous reports, 17, 22 and strongly expressed on tumorsphere (bottom). Meanwhile, the cells positive for TRIM11 staining also displayed strong CD133 immunopositivity in both tumorsphere and monolayer cells.
For nestin expression study, U-251 was used as a positive control as previously described. 27 Our results showed that nestin expressed at elevated levels in almost all the glioma-derived GSCs tested and more robustly in all GBM-GSCs and NSCs (Table 1 and Supplementary Figure S1a) .
Taken together, our results suggest that the levels of TRIM11 correlate with the malignancy of glioma and potentially with the prognosis of glioma patients. Compared with CD133 and nestin, TRIM11 might be a more specific indicator for GSCs as it is upregulated only in malignant glioma-derived GSCs but not in NSCs or low-grade glioma-derived GSCs.
TRIM11 mRNA levels correlate with differentiation status and CD133 mRNA levels in gliomas When cultured in serum-free medium, which allows for the maintenance of an undifferentiated stem cell state, glioma cells form tumorspheres, along with an increased expression of CD133. 28, 29 To further investigate the correlation between Figure S2c) . By comparing with early and late passages of DB32-GSC and HuTuP01-GSC, we found both TRIM11 and CD133 decreased after continuous expansion (Figure 2d ), further confirming that TRIM11 levels are correlated with differentiation status and CD133 levels of GSCs. The stem cell character of HuTuP01-GSC was further identified by differentiation assay (Supplementary Figure S2d) , confirming their multipotential nature.
Downregulation of TRIM11 suppresses proliferation, migration and invasion of glioma cells and inhibits EGFR expression, MAPK signaling pathway and transcription of HB-EGF and CCND1
To investigate the potential oncogenic function of TRIM11 in glioma, we knocked down TRIM11 in glioma cells through RNA interference. Both protein and mRNA levels of TRIM11 were The invasive behavior of malignant gliomas limits the effectiveness of local therapies and contributes to their poor prognosis. 30 Therefore, wound closure assay (Figure 3b ) was performed to compare the migration capability between controls and TRIM11 knockdown U-251 cells. TRIM11-downregulating cells displayed a slower migration capability than control: while control cells were able to migrate in and fill up the gap in 30 h, the gap was only partially filled in siTRIM11 transfectants at the same time. (c) HuTuP01-GSC was cultured with differentiation medium for different time points and switched back to SCM followed by RNA isolation at the indicated time points. (d) Early and late passages of DB32-GSC and HuTuP01-GSC were collected and RNA was isolated. Quantitative reverse-transcriptase-PCR was then performed to measure the mRNA levels of TRIM11 and CD133, and ACTB was an internal control. *Po0.05, **Po0.01, ***Po0.001.
TRIM11 has oncogenic functions in gliomas K Di et al S4a). The role of TRIM11 on cell invasion was next measured using the Matrigel invasion chamber assay (Figure 3c) . In both the D-54 and U-251 cells, suppression of TRIM11 inhibited cell invasion, and the difference was statistically significant (Po0.05).
In GBMs, amplification and/or mutation of the gene encoding EGFR occurs in up to 60% of tumors, and the constitutive activation of EGFR can promote glioma cell proliferation and invasion. 31 As one of the main intracellular protein cascades of EGFR, deregulated MAPK pathway due to activation of EGFR will influence a diverse array of vital cellular functions, such as proliferation, survival and differentiation. 32, 33 We next evaluated the expression levels of EGFR and phosphorylation status of MAPK in glioma cells having different TRIM11 levels. As shown in Figure 3d and Supplementary Figure S4b , downregulation of TRIM11 led to decreased expression of EGFR, p-c-Raf, p-MEK1/2 (MAPK/ERK kinases 1/2), and p-44/42MAPK, suggesting that TRIM11 might regulate the EGFR/MAPK pathway. Meanwhile, PI3K-AKT signaling, another downstream of EGFR, was not affected by TRIM11 (Supplementary Figure S4c) . Next, we used the human EGF/PDGF (epidermal growth factor/ plateletderived growth factor) signaling PCR array to study whether TRIM11 differentially regulate the transcription of any Quantitative reverse-transcriptase-PCR was performed to compare the mRNA levels of EGFR (left), HB-EGF (middle) and CCND1 (right) between siTRIM11 (si-4) or siCon transfectants, and ACTB was an internal control. *Po0.05, **Po0.01, ***Po0.001.
TRIM11 has oncogenic functions in gliomas K Di et al genes in the EGF/PDGF signaling pathway. Table 2 showed the profile of various differentially expressed genes with fold changes of X2. There were six upregulated and four downregulated genes in D-54 siTRIM11 (si-4) transfections, and one upregulated and four downregulated genes in U-251 siTRIM11 (si-4) transfections. Among all the genes changed, downregulation of two genes, HB-EGF (heparin-binding EGF-like growth factor) and CCND1 (Cyclin D1), was found in both the cell lines. Meanwhile, the expression of EGFR was not significantly changed. To confirm these results, we measured again mRNA levels of EGFR, HB-EGF and CCND1 using different primers (Figure 3e ). Our results showed that both HB-EGF and CCND1 were dramatically decreased, while there was no statistically difference on EGFR in siTRIM11 transfectants. Similar results were found in LN229 cells transfected with three different siTRIM11s (Supplementary Figure S4d) . To compare with knockdown experiments, gain-of-function studies were further performed. Following transfection of a FlagTrim11 construct (Supplementary Figure S5a) , both the levels of EGFR and the activity of MAPK pathway were increased (Supplementary Figure S5b) , further confirming an oncogenic function of TRIM11 through promoting the accumulation of EGFR and activity of MAPK cascade.
Overexpression of TRIM11 promotes tumorsphere formation and proliferation in vitro and tumor growth in vivo To further test the oncogenic function of TRIM11 both in vitro and in vivo, transient and stable TRIM11 overexpressing transfectants (pDsRed2-Trim11) were generated using mouse GL261 glioma cells. Expression of TRIM11 mRNA was analyzed in Figure 4a (stable transfection) and Supplementary Figure S5c Figure  S5d) TRIM11 overexpressing cells. Interestingly, large tumorspheres were detected in stable pDsRed2-Trim11 cells but not in control cells (Figure 4a, right) . This morphological change supports our hypothesis that TRIM11 has an important role in achieving/ maintaining the stem cell state and led us to test the sphere formation capability induced by upregulation of TRIM11. As shown in Figure 4b , overexpression of TRIM11 significantly promoted tumorsphere formation (upper panel), and the size of spheres driven from pDsRed2-Trim11 cells was significantly larger than that of control cells (right). Meanwhile, cell proliferation rate was dramatically increased in pDsRed2-Trim11 cells when cells grew on Matrigel-coated surface (Figure 4b, lower panel) .
Based on our in vitro data (which suggest that TRIM11 significantly increases glioma cell proliferation and invasion), we then tested whether TRIM11 overexpression can promote glioma growth in vivo. Stable pDsRed2-Trim11-GL261 cells and control cells were injected subcutaneous into BALB/C nu/nu mice. The tumors generated by the pDsRed2-Trim11-GL261 cells were more than three times larger (both tumor volume and weight) than the tumors generated by the control cells (Figures 4c and d) . Furthermore, macroscopic examination of these tumors showed increased vascularization, and extensive areas of necrosis characteristics well described to predict an aggressive phenotype in glial tumors. These findings further support that TRIM11 overexpression enhances glioma cell ability to form aggressive tumors and correlate with our findings in human specimens, where high TRIM11 levels correlated with poor prognosis.
DISCUSSION
Significant progress has been made on investigating the cellular, molecular, and genetic changes involved in malignant gliomas aggressive biological behavior, treatment resistance and poor survival. Recently, identifying and targeting the GSCs has been considered as a powerful tool for developing therapeutic strategies, as GSCs are chemo-and radiotherapy-resistant and possess self-renewal, differentiation and multi-potentiality, leading to therapy failure and recurrence. 8, 9, 34 However, this is a difficult task as majority of the GSC markers described to date, such as CD133 and nestin, are also present at similar or higher levels in the adult NSCs. Thus, a cancer therapy targeted using these ubiquitous and non-specific markers would risk eradicating reserves of normal self-renewing NSCs. Furthermore, animals with decreased neurogenesis have impaired performance on hippocampus-dependent learning tasks, 35 suggesting that ablation of NSCs in the course of glioma therapy might lead to undesirable cognitive side-effects.
Here, we provided evidence that TRIM11 may act as a novel marker for malignant gliomas. TRIM11 expression levels correlated with the glioma malignancy, similar to those of CD133 and nestin-whose expression levels are indicators for grade levels of Abbreviations: EGF, epidermal growth factor; PDGF, platelet-derived growth factor; TNF, tumor-necrosis factor; TRIM 11, tripartite motif-containing protein 11. Note: Human EGF/PDGF Signaling PCR Array was performed to compare gene expression changes by TRIM11 downregulation. Genes with 4two-fold regulation were considered as significant difference. The shading indicates the downregulation with > two-fold change.
TRIM11 has oncogenic functions in gliomas K Di et al gliomas and are well-published as prognostic markers. 4, 5 More importantly, high TRIM11 were detected only in malignant gliomaderived GSCs and tissue sections (Table 1, Figure 1a and Supplementary Figure S1 ), suggesting that TRIM11 has the potential to become a specific GSC marker. In addition, TRIM11 levels, concurrent with CD133, were associated with differentiation status of cells (Figure 2) . Concurrence between TRIM11 and CD133 not only occurred at mRNA levels but also at patterns of protein expression in cells. Co-expression of these two proteins was detected in both tissue sections (Figure 1b) and GSCs (Figure 1c) . Interestingly, even though CD133 is a cell surface marker, immunofluorescence staining of CD133 generally shows a diffused cytoplasmic staining in our study and others, 36, 37 possibly due to permeabilization of the cell membranes by fixative that inadvertently damage surface marker antigens. 38 We not only demonstrated for the first time that TRIM11 acts as a malignant glioma marker but also provided evidence that TRIM11 may exert its oncogenic function through promoting cell proliferation (Figures 3a and 4b and Supplementary Figure S3c) , migration (Figure 3b and Supplementary Figure S4a) and invasion (Figure 3c ). Most importantly, our results indicated that TRIM11 exerts its effect through EGFR oncogenic pathway. A decreased expression of EGFR and weakened activity of Raf/MEK/ERK1/2 MAPK pathway were found in TRIM11 knocked down GBM cells (Figure 3d and Supplementary Figure S4b) , which harbor the wild-type EGFR gene. 39 By contrast, overexpressing TRIM11 increased the expression of EGFR and enhanced the activity of MAPK pathway (Supplementary Figure S5b) .
HB-EGF is a heparin-binding member of the EGF family 40 and is upregulated in response to oncogenesis. 41, 42 Co-expression of HB-EGF with the amplified EGFR has been found in malignant gliomas, resulting in the formation of an autocrine loop. 43 By binding and activating EGFR, HB-EGF in turn triggers EGFR downstream signaling pathways, including MAPKs, which then TRIM11 has oncogenic functions in gliomas K Di et al induce a rapid and sustained induction of HB-EGF mRNA expression and secretion of HB-EGF. 44 Besides being a ligand for EGFR, HB-EGF also induces the expression of matrix metalloproteinases MMP-9 and MMP-3 and elevates activation of cyclin D1 promoter, 45 suggesting a role of HB-EGF as a potent inducer of tumor growth and angiogenesis. In our study, although the mRNA levels of EGFR were not affected by TRIM11 downregulation, a significant decrease on HB-EGF and CCND1 mRNA levels was detected in TRIM11 knockdown cells (Table 2 and Figure 3e ). By comparison, overexpression of TRIM11 increased the HB-EGF mRNA levels ( Supplementary Figures S5c  and d) . Further studies will be needed to identify: (1) whether TRIM11 directly regulates the transcription of HB-EGF and/or CCND1, or alternatively, downregulation of HB-EGF is a consequence of reduced EGFR levels and weakened MAPK pathway; or (2) whether TRIM11 may modulate the process of EGFR ubiquitination and degradation.
Finally, we provided evidence for the first time that overexpression of TRIM11 promotes tumorsphere formation in vitro and tumor growth in vivo (Figure 4 ). These in vivo results further support the hypothesis that TRIM11 overexpression predicts the development of large, vascular and necrotic tumors associated with poor prognosis.
In summary, our study profiles the gene expression pattern of TRIM11 in various grade glioma specimens, as well as multiple GSCs, stable serum-grown glioma cell lines and NSCs, and finds a strong positive correlation among TRIM11, CD133, and nestin in high-grade GSCs. In addition, we investigated the oncogenic function of TRIM11 on proliferation, migration and invasion, demonstrating that TRIM11 may modulate EGFR expression and MAPK pathway and bring the first evidence that TRIM11 overexpression promotes glial tumor growth in vivo. This finding expands our knowledge of the TRIM11 biology from its known roles in the normal brain development and Alzheimer's neurotoxicity into cancer biology, while opening the door for a novel new area of glioma biology study, with the potential to identify new translational targets and/or strategies.
MATERIALS AND METHODS

Glioma tissues, cells and media
Approval from the Institutional Review Board was obtained at the University of California Irvine Medical Center and Children's Hospital of Orange County. Surgical specimens of brain tumors (Table 1) were obtained from patients who had undergone tumor resection with the neuropathological review completed by a specialty neuropathologist. NSCs (SC23, SC27, SC30) were derived from the brains of premature neonates by Dr Philip Schwartz.
26 HuTuP01 GBM-GSCs were a gift from Dr David Panchision (Children's National Medical Center). 46 As previously described, 14 both NSCs and GSCs were cultured in undifferentiated conditions on Matrigel-coated dishes in 1:1 Dulbecco's modified Eagle's medium (DMEM):F12 medium (Irvine Scientific, Santa Ana, CA, USA), containing 10% BIT9500 (Stem Cell Technologies, Vancouver, BC, Canada), 292 mg/ml glutamine (Irvine Scientific), 40 ng/ml fibroblast growth factor, 20 ng/ml EGF and 20 ng/ml PDGF. For expansion, one-half of this medium was replaced every other day, and the cultures were passaged every 7 days or when confluent using Non-enzymatic Cell Dissociation Solution (Sigma, St Louis, MO, USA). All our GSCs are able to form spheres when grown on non-adherent surfaces. The GSCs express glial fibrillary acidic protein when they are grown under conditions favoring glial differentiation and bIIItubulin when they are grown under conditions favoring neural differentiation, confirming their multipotential nature (Supplementary Figure S2d) .
The stable human glioma cell lines D-54 MG and U-251 MG were gifts from Dr Darrell Bigner (Duke University, Durham, NC), LN229 was obtained from Dr Martin Jadus (VA Long Beach Hospital) and U-87 MG as well as mouse cell line GL261 were gifts from Dr Florence Hofman (University of Southern California). All the differentiated malignant glioma cell lines were cultured in a high glucose 1:1 DMEM/F12 medium (Irvine Scientific) containing 2 mM L-glutamine (Gibco/Invitrogen, Grand Island, NY, USA), 10% fetal bovine serum (Omega Scientific, Tarzana, CA, USA) and 1% penicillin/streotomycin (Gibco/Invitrogen). All cells were cultured at 37 1C in a humidified incubator with 5% CO 2 .
Quantitative reverse-transcriptase-PCR analysis Total RNA was extracted using RNeasy Mini Kit (Qiagen, Germantown, MD, USA), and cDNA was generated using the iScript cDNA Synthesis Kit (Biorad, Hercules, CA, USA). Quantitative PCR reactions (iQ SYBR Green Supermix, Bio-rad) were conducted using a Bio-Rad CFX96 Real-time System, and the gene expression levels were normalized to those of ACTB. The primers were described in Supplementary Methods.
Immunohistochemical and immunofluorescent staining VECTASTAIN ABC kit (Vector Laboratories, Burlingame, CA, USA) was used for immunohistochemical staining. Formalin-fixed, paraffin-embedded tissue sections (5 mm) were deparaffinized and rehydrated. After antigen retrieval, the endogenous peroxidase activity was blocked with 1% H 2 O 2 in phosphate-buffered saline for 20 min. The sections were incubated with 5% normal goat serum and then exposed to rabbit anti-TRIM11 antibody (1:40, ProteinTech Group, Chicago, IL, USA) at 4 1C overnight, followed by incubation with biotinylated anti-rabbit IgG for 1 hour at room temperature, and counterstained by hematoxylin and eosin. Slides were then mounted with Permount (Fisher Scientific, Fair Lawn, NJ, USA). For immunofluorescent double staining, the cells or tissue sections were first incubated with rabbit anti-TRIM11 and fluorescein isothiocyanate-conjugated anti-rabbit secondary antibody (Millipore, Billerica, MA, USA) and then CD133/1 (AC133)-phycoerythrin antibody (Miltenyi Biotec, Auburn, CA, USA). Nuclei were counterstained with DAPI (4 0 -6-diamidino-2-phenylindole) and slides were mounted with IMMU-MOUNT (Thermo Scientific, Rockford, IL, USA).
siTRIM11 transfection
Four human FlexiTube siRNAs targeting TRIM11 (SI00153230, SI00153237, SI00153244 and SI00153251) and negative control siRNA (1022076) were purchased from Qiagen and were transfected into cells using HiPerFect transfection reagent (Qiagen). One siTRIM11 (si-4) was found to knock down TRIM11 expression most efficiently and was used in most of the experiments.
Plasmid construction and transient and/or stable transfection assay pcDNA3.1/Zeo Flag-Trim11 and pDsRed2-Trim11 were gifts from Dr Seok Jong Hong (Northwestern University). Briefly, mouse brain mRNA was used to amplify full-length TRIM11 by reverse-transcriptase-PCR followed by cloning into pcDNA3.1/Zeo vector and pDsRed2-C1 vector. 24 Transfection was performed using FuGene 6 (Roche, Indianapolis, IN, USA). For transient transfection, the cells were analyzed 72 h after transfection. For generation of stable transfectants, the cells were selected by 0.4 mg/ml of G418 (InvivoGen, San Diego, CA, USA) for 2 weeks.
Western blotting
Antibodies with detailed descriptions are provided in Supplementary Methods. The images were exposed by KODAK M35A X-OMAT Processor (EASTMAN KODAK Company, Rochester, NY, USA).
BrdU cell proliferation analysis
Cell proliferation rates were determined by BrdU incorporation according to the manufacture's recommendation (Calbiochem, La Jolla, CA, USA). Briefly, the cells were incubated with BrdU Label for 24 h and then fixed. Monoclonal anti-BrdU antibody was added, followed by peroxidaseconjugated secondary antibody. The BrdU incorporation was measured at dual wavelengths of 450 and 570 nm, using a Model 680 Microplate Reader (Bio-Rad).
MTT assay Cells (6 Â 10 3 /well) were seeded into 96-well plates. Before testing, MTT solution (5 mg/ml; 20 ml/well) was added, and cells were incubated at 37 1C for 5 h. The culture medium was then aspirated and dimethyl sulfoxide (200 ml/well, Fisher Scientific) was added to dissolve the dark blue crystals. The absorbance was measured at a wavelength of 570 nm.
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